Amneal Pharmaceuticals, Inc.
http://www.amneal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amneal Pharmaceuticals, Inc.
Amneal Kicks Off China Business With First Approval
Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.
Amneal Submits Modest Guidance Raise Following Strong Second Quarter
Amneal now expects an additional $50m in net revenue this year, revising its revenue expectations up to between $2.3bn and $2.4bn following a successful second quarter.
Amneal Goes After ProAir, Lumigan And Diprivan With Latest Filings
With a continuing focus on complex generics, Amneal has revealed a trio of US filings targeting ProAir, Lumigan and Diprivan.
FDA Demands More Information For Amneal Parkinson’s Disease Drug
Amneal says it will work closely with the FDA after seeing its application for the company’s IPX203 cardbidopa/levodopa extended-release turned down for approval by the agency.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice